ILB 3101
Alternative Names: EP-0028; ILB-3101Latest Information Update: 28 Jan 2026
At a glance
- Originator Innolake Biopharm
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 22 Jan 2026 ILB-3101 licensed to Ellipses Pharma worldwide excluding greater China
- 22 Jan 2026 Ellipses plans a phase-I trial for Cancer in USA and Europe (IV),
- 30 Oct 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, In adults, In the elderly, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06426680)